Silicon Motion Technology Corporation (NASDAQ: SIMO) reported that for the second quarter of 2012, net sales increased 8.8% quarter-over-quarter to US$69.7 million from US$64.0 million in the first quarter of 2012.
Net income (non-GAAP) increased in the second quarter to US$14.6 million or US$0.42 per diluted ADS from a net income of US$14.0 million or US$0.41 per diluted ADS in the first quarter of 2012.
Silicon Motion Technology Corporation is a fabless semiconductor company that designs, develops and markets high performance, low-power semiconductor solutions for the multimedia consumer electronics market. We have two major product lines, mobile storage and mobile communications. Our mobile storage business is composed of microcontrollers used in NAND flash memory storage products such as flash memory cards, USB flash drives, SSDs, and embedded flash applications. Our mobile communications business is composed primarily of handset transceivers and mobile TV IC solutions. For more information about Silicon Motion Technology Corporation visit www.siliconmotion.com.
MercadoLibre, Inc. (NASDAQ: MELI) intends to release financial results for its second fiscal quarter ended June 30, 2012 on August 2nd, 2012 after the close of the day's trading.
Founded in 1999, MercadoLibre (www.mercadolibre.com) is Latin America's leading e-commerce technology company. Through its primary platforms, MercadoLibre.com and MercadoPago.com, it provides solutions to individuals and companies buying, selling, advertising, and paying for goods and services online.
MercadoLibre.com serves millions of users and creates a market for a wide variety of goods and services in an easy, safe and efficient way. The site is among the top 50 in the world in terms of page views and is the leading retail platform in unique visitors in each country in which it operates according to metrics provided by comScore Networks. MercadoLibre maintains a leadership position in 12 Latin American countries. The Company is listed on NASDAQ (NASDAQ:MELI) following its initial public offering in 2007. For more information about the company visit: http://investor.mercadolibre.com.
CRWE launched CRWE Real Estate to provide a global portal for property listings at a fee of only $1 a day. CRWE Real Estate mission is to empower consumers with information and tools to make smart decisions about homes, real estate and mortgages. CRWE Direct is an online business-to-business marketplace for manufacturers and small to large businesses to purchase various types of merchandise. Manufacturers may start downloading their product immediately, free of charge during the next six months. Thereafter, there will be various annual fees. The listing process and image loading for both sites are user-friendly.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.
StemCells, Inc. (NASDAQ: STEM) reported that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company and its collaborators for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05).
The award is to fund preclinical development of StemCells' proprietary HuCNS-SC(r) product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury. The award will provide funding over a maximum four-year period, with the goal of filing an investigational new drug (IND) application to begin clinical testing in that time. CIRM deferred a decision on the Alzheimer's disease application submitted by StemCells and referred the application back to CIRM's Grants Working Group for further consideration.
CIRM is expected to review the application again at the next meeting of its governing board currently scheduled for September 6th.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim safety data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.